Search

Your search keyword '"Fratto, M. A."' showing total 3 results
Start Over Author "Fratto, M. A." Topic bone metastasis
3 results on '"Fratto, M. A."'

1. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.

Author

Santini, D., Tampellini, M., Vincenzi, B., Ibrahim, T., Ortega, C., Virzi, V., Silvestris, N., Berardi, R., Masini, C., Calipari, N., Ottaviani, D., Catalano, V., Badalamenti, G., Giannicola, R., Fabbri, F., Venditti, O., Fratto, M. E., Mazzara, C., Latiano, T. P., and Bertolini, F.

Subjects
*BONE cancer treatment, *NATURAL history, *BONE metastasis, *COLON cancer, *ITALIANS, *ZOLEDRONIC acid, *SURVIVAL analysis (Biometry), *SPINE, *DISEASES
Abstract

Background Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC. Patients and methods This retrospective, multicenter, observational study of 264 patients with CRC involving bone examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency, zoledronic acid therapy, and disease outcomes. Results Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most common site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time from CRC diagnosis to bone metastases was 11.00 months; median time to first SRE thereafter was 2.00 months. Radiation and pathologic fractures affected 45% and 10% of patients, respectively; 32% of patients had no reported SREs. Patients survived for a median of 7.00 months after bone metastases diagnosis; SREs did not significantly affect survival. Subgroup analyses revealed that zoledronic acid significantly prolonged median time to first SRE (2.00 months versus 1.00 month, respectively, P = 0.009) and produced a trend toward improved overall survival versus no zoledronic acid. Conclusion This study illustrates the burden of bone metastases from CRC and supports the use of zoledronic acid in this setting. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

2. New molecular targets in bone metastases

Author

Evaristo Maiello, Alice Zoccoli, Antonio Russo, Elisabetta Riva, Daniele Santini, Nicola Silvestris, Maria Elisabetta Fratto, Sergio Rizzo, Giuseppe Colucci, Lucia Lombardi, Bruno Vincenzi, Sara Galluzzo, C. Gucciardino, Francesco Pantano, Giuseppe Tonini, Santini, D., Galluzzo, S., Zoccoli, A., Pantano, F., Fratto, M., Vincenzi, B., Lombardi, L., Gucciardino, C., Silvestris, N., Riva, E., Rizzo, S., Russo, A., Maiello, E., Colucci, G., and Tonini, G.

Subjects
Oncology, medicine.hormone, medicine.medical_specialty, Pathology, Cathepsin K, Proto-Oncogene Proteins pp60(c-src), Antineoplastic Agents, Bone Neoplasms, Bone Neoplasm, Antibodies, Monoclonal, Humanized, Endothelin, Metastasis, Antineoplastic Agent, Endothelins, Bone metastases, Molecular targets, Animals, Antibodies, Monoclonal, Denosumab, Humans, RANK Ligand, Medicine (all), Radiology, Nuclear Medicine and Imaging, Internal medicine, Medicine, Radiology, Nuclear Medicine and imaging, Molecular target, biology, Animal, business.industry, Cancer, Bone metastasis, General Medicine, medicine.disease, Clinical trial, Bone metastase, RANKL, Cancer cell, biology.protein, business, Human, medicine.drug
Abstract

Bone metastases have a major impact on morbidity and on mortality in cancer patients. Despite its clinical relevance, metastasis remains the most poorly elucidated aspect of carcinogenesis. The biological mechanisms leading to bone metastasis establishment have been referred as " vicious circle," a complex network between cancer cells and the bone microenvironment. This review is aimed to underline the new molecular targets in bone metastases management other than bisphosphonates. Different pathways or molecules such as RANK/RANKL/OPG, cathepsin K, endothelin-1, Wnt/DKK1, Src have recently emerged as potential targets and nowadays preclinical and clinical trials are underway. The results from those in the advanced clinical phases are encouraging and underlined the need to design large randomised clinical trials to validate these results in the next future.Targeting the bone by preventing skeletal related events (SREs) and bone metastases has major clinical impact in improving survival in bone metastatic patients and in preventing disease relapse in adjuvant setting. © 2010 Elsevier Ltd.

Published
2010

3. Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases

Author

Alfredo Berruti, Giuseppe Perrone, Chiara Della Pepa, Bruno Vincenzi, Donatella Grasso, Antonio Russo, Daniele Santini, Rosa Maria Tomasino, Roberto Sabbatini, Gaia Schiavon, Mauro Papotti, Laura Godio, Andrea Onetti Muda, Vincenzo Denaro, Nicola Papapietro, Ilaria Roato, Giuseppe Tonini, Camillo Porta, Francesco Pantano, Maria Elisabetta Fratto, Alessandro Del Conte, Santini, D, Perrone, G, Roato, I, Godio, L, Pantano, F, Grasso, D, Russo, A, Vincenzi, B, Fratto, M, Sabbatini, R, Della Pepa, C, Porta, C, Del Conte, A, Schiavon, G, Berruti, A, Tomasino, R, Papotti, M, Papapietro, N, Onetti Muda, A, Denaro, V, and Tonini, G

Subjects
medicine.medical_specialty, Settore MED/06 - Oncologia Medica, Physiology, Clinical Biochemistry, colorectal cancer, Bone Neoplasms, Bone remodeling, Metastasis, Prostate cancer, breast cancer, Osteoprotegerin, Internal medicine, medicine, Humans, bone metastasi, biology, Receptor Activator of Nuclear Factor-kappa B, business.industry, Medicine (all), Bone metastasis, Cell Biology, medicine.disease, Primary tumor, bone metastasis, Immunohistochemistry, Endocrinology, RANKL, Cancer research, biology.protein, business
Abstract

Receptor activator of NFκB ligand (RANKL), RANK, and osteoprotegerin (OPG) represent the key regulators of bone metabolism both in normal and pathological conditions, including bone metastases. To our knowledge, no previous studies investigated and compared RANK expression in primary tumors and in bone metastases from the same patient. We retrospectively examined RANK expression by immunohistochemistry in 74 bone metastases tissues from solid tumors, mostly breast, colorectal, renal, lung, and prostate cancer. For 40 cases, tissue from the corresponding primary tumor was also analyzed. Sixty-six (89%) of the 74 bone metastases were RANK-positive and, among these, 40 (59.5%) showed more than 50% of positive tumor cells. The median percentage of RANK-positive cells was 60% in primary tumors and metastases, without any statistically significant difference between the two groups (P = 0.194). The same percentage was obtained by considering only cases with availability of samples both from primary and metastasis. Our study shows that RANK is expressed by solid tumors, with high concordance between bone metastasis and corresponding primary tumor. These data highlight the central role of RANK/RANKL/OPG pathway as potential therapeutic target not only in bone metastasis management, but also in the adjuvant setting.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results